Abstract: Disclosed is a skin external preparation containing a triterpenic acid typified by ursolic acid. For obtaining a skin external preparation having excellent storage stability by improving the dissolution stability of the triterpenic acid and the like, 4-alkylresorcinol such as 4-n-butylresorcinol is added into a skin external preparation containing a triterpenic acid and the like such as benzyl ursolate.

Abstract: Disclosed is an agent for skin external preparation which is hardly reduced in viscosity even when stored for a long period under extreme high temperature storage conditions and is therefore stable. The preparation is in an emulsion form, and comprises (1) an alginic acid polyol ester having an esterification degree ranging from 75 to 95% (e.g., alginic acid propylene glycol ester) and/or a salt thereof; (2) a polyvalent metal ion (e.g., a calcium ion); and (3) a 4-alkylresolcinol (e.g., 4-n-butylresolcinol) and/or a salt thereof.

Abstract: Disclosed is a skin external preparation containing a triterpenic acid typified by ursolic acid. For obtaining a skin external preparation having excellent storage stability by improving the dissolution stability of the triterpenic acid and the like, 4-alkylresorcinol such as 4-n-butylresorcinol is added into a skin external preparation containing a triterpenic acid and the like such as benzyl ursolate.

Abstract: Disclosed is an agent for skin external preparation which is hardly reduced in viscosity even when stored for a long period under extreme high temperature storage conditions and is therefore stable. The preparation is in an emulsion form, and comprises (1) an alginic acid polyol ester having an esterification degree ranging from 75 to 95% (e.g., alginic acid propylene glycol ester) and/or a salt thereof; (2) a polyvalent metal ion (e.g., a calcium ion); and (3) a 4-alkylresolcinol (e.g., 4-n-butylresolcinol) and/or a salt thereof.

Abstract: The present invention relates to a compound of the formula [I]: wherein A is lower alkylene or lower alkenylene; R1 is lower alkyl, hydroxy(lower)alkyl, protected hydroxy(lower)alkyl, amino(lower)alkyl or protected amino(lower)alkyl, and R2 is hydrogen or amino protecting group, or R1 and R2 are bonded together and form lower alkylene; R3 and R5 are independently amino or protected amino; and R4 is carboxy or protected carboxy, or a pharmaceutically acceptable salt thereof, a process for preparing a compound of the formula [I], and a pharmaceutical composition comprising a compound of the formula [I] in admixture with a pharmaceutically acceptable carrier.

Abstract: The present invention relates to a compound of the formula [I]: wherein A is lower alkylene or lower alkenylene; R1 is lower alkyl, hydroxy(lower)alkyl, protected hydroxy(lower)alkyl, amino(lower)alkyl or protected amino(lower)alkyl, and R2 is hydrogen or amino protecting group, or R1 and R2 are bonded together and form lower alkylene; R3 and R5 are independently amino or protected amino; and R4 is carboxy or protected carboxy, or a pharmaceutically acceptable salt thereof, a process for preparing a compound of the formula [I], and a pharmaceutical composition comprising a compound of the formula [I] in admixture with a pharmaceutically acceptable carrier.